Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells

BMC Biotechnology

Volumn 8, Issue , 2008, Pages

  Funaro, Ada ^a   Gribaudo, Giorgio ^b   Luganini, Anna ^b   Ortolan, Erika ^a   Lo Buono, Nicola ^a   Vicenzi, Elisa ^c   Cassetta, Luca ^c   Landolfo, Santo ^b   Buick, Richard ^d   Falciola, Luca ^e   Murphy, Marianne ^e   Garotta, Gianni ^e   Malavasi, Fabio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d FUSION ANTIBODIES LTD   (United Kingdom)

^e RiboVax Biotechnologies   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; IMMUNOLOGY; INTERNET; MONOCLONAL ANTIBODIES;

ANTIVIRALS; B CELLS; B-LYMPHOCYTES; CELL BIOLOGIES; CLINICAL APPLICATIONS; DRUG-RESISTANT STRAINS; EFFICIENT TECHNOLOGIES; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; INFECTIOUS DISEASE; MONOCLONAL ANTIBODIES (MABS); OVERALL COSTS; PATHOGENIC AGENTS; SIDE EFFECTS; TARGET CELLS; THERAPEUTIC ANTIBODIES; THERAPEUTIC TOOLS;

SURFACE PLASMON RESONANCE;

CD23 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOMEGALOVIRUS ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR 9; GLYCOPROTEIN B, SIMPLEXVIRUS; GLYCOPROTEIN H, CYTOMEGALOVIRUS; IMMUNOGLOBULIN E RECEPTOR; RECOMBINANT PROTEIN; TLR9 PROTEIN, HUMAN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROCESS DESIGN; PROCESS TECHNOLOGY; VIRUS INFECTIVITY; AMINO ACID SEQUENCE; BIOSYNTHESIS; CELL CULTURE; CELL LINE; CYTOMEGALOVIRUS; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REPRODUCIBILITY; SERODIAGNOSIS; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BASE SEQUENCE; CELL LINE; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RECEPTORS, IGE; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; TOLL-LIKE RECEPTOR 9; VIRAL ENVELOPE PROTEINS;

EID: 60549097906     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-8-85     Document Type: Article

References (54)

1. Brekke OH Sandlie I Therapeutic antibodies for human diseases at the draw of the twenty-first century Nat Rev Drug Discov 2003, 2:52-62 12509759
2. Reichert JM Rosensweig CJ Faden LB Dewitz MC Monoclonal antibody successes in the clinic Nat Biotechnol 2005, 23:1073-8 16151394
3. Hoogenboom HR Selecting and screening recombinant antibody libraries Nat Biotechnol 2005, 23:1105-16 16151404
4. Lonberg N Human antibodies from transgenic animals Nat Biotechnol 2005, 23:1117-25 16151405
5. Sawyer LA Antibodies for the prevention and treatment of viral diseases Antiviral Res 2000, 47:57-77 10996394
6. Casadevall A Dadachova E Pirofski LA Passive antibody therapy for infectious diseases Nat Rev Microbiol 2004, 2:695-703 15372080
7. Simmons CP Bernasconi NL Suguitan AL jr Mills K Ward JM Van Vinh Chau N Hien TT Sallusto F Ha DQ Farrar J de Jong MD Lanzavecchia A Subbarao K Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza PLoS Med 2007, 4:5 e178 1880850 17535101
8. Lanzavecchia A Corti D Sallusto F Human monoclonal antibodies by immortalization of memory B cells Curr Opin Biotechnol 2007, 18:523-8 18063358
9. Steinitz M Klein G Koskimies S Makel O EB virus-induced B lymphocyte cell lines producing specific antibodies Nature 1977, 269:420-422 198669
10. Casali P Inghirami G Nakamura M Davies TF Notkins AL Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV Science 1986, 234:476-9 3020687
11. Tsuchiyama L Kieran J Boyle P Wetzel GD Synergy between anti-CD40 MAb and Epstein-Barr virus in activation and transformation of human B lymphocytes Hum Antibodies 1997, 8:43-7 9265505
12. Traggiai E Becker S Subbarao K Kolesnikova L Uematsu Y Gismondo MR Murphy BR Rappuoli R Lanzavecchia A An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus Nat Med 2004, 10:871-5 15247913
13. Landolfo S Gariglio M Gribaudo G Lembo D The human cytomegalovirus Pharmacol Ther 2003, 98:269-97 12782241
14. Nichols WG Corey L Gooley T Davis C Boeckh M High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection J Infect Dis 2002, 185:273-282 11807708
15. Streblow DN Orloff SL Nelson JA Acceleration of allograft failure by cytomegalovirus Curr Opin Immunol 2007, 19:577-582 17716883
16. Li J Sai T Berger M Chao Q Davidson D Deshmukh G Drozdowski B Ebel W Harley S Henry M Jacob S Kline B Lazo E Rotella F Routhier E Rudolph K Sage J Simon P Yao J Zhou Y Kavuru M Bonfield T Thomassen MJ Sass PM Nicolaides NC Grasso L Human antibodies for immunotherapy development generated via a human B cell hybridoma technology Proc Nat Acad Sci USA 2006, 103:3557-3562 1383494 16505368
17. Carter PJ Potent antibody therapeutics by design Nat Rev Immunol 2006, 6:343-57 16622479
18. Ashkar AA Bauer S Mitchell WJ Vieira J Rosenthal KL Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2 J Virol 2003, 77:8948-56 167233 12885911
19. Klinman DM Immunotherapeutic uses of CpG oligodeoxynucleotides Nat Rev Immunol 2004, 4:249-58 15057783
20. Luganini A Caposio P Landolfo S Gribaudo G Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry Antimicrob Agents Chemother 2008 2258505 18180342
21. Satoh M Yasuda T Higaki T Goto M Tanuma S Ide T Furuichi Y Sugimoto M Innate apoptosis of human B lymphoblasts transformed by Epstein-Barr virus: Modulation by cellular immortalization and senescence Cell Struct Funct 2003, 28:61-70 12655152
22. Altmann M Hammerschmidt W Epstein-Barr virus provides a new paradigm: A requirement for the immediate inhibition of apoptosis PLoS Biol 2005, 3:e404 1283332 16277553
23. Sugimoto M Tahara H Ide T Furuichi Y Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus Cancer Res 2004, 64:3361-4 15150084
24. Krieg AM Yi AK Matson S Waldschmidt TJ Bishop GA Teasdale R Koretzky GA Klinman DM CpG motifs in bacterial DNA trigger direct B-cell activation Nature 1995, 374:546-9 7700380
25. Hartmann G Weeratna RD Ballas ZK Payette P Blackwell S Suparto I Rasmussen WL Waldschmidt M Sajuthi D Purcell RH Davis HL Krieget AM Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo J Immunol 2000, 164:1617-24 10640783
26. Liang H Nishioka Y Reich CF Pisetsky DS Lipsky PE Activation of human B cells by phosphorothioate oligodeoxynucleotides J Clin Invest 1996, 98:1119-29 507533 8787674
27. Kato A Homma T Batchelor J Hashimoto N Imai S Wakiguchi H Saito H Matsumoto K Interferon-alpha/beta receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006 BMC Immunol 2003, 4:8 183869 12887736
28. Ladell K Dorner M Zauner L Berger C Zucol F Bernasconi M Niggli FK Speck RF Nadal D Immune activation suppresses initiation of lytic Epstein-Barr virus infection Cell Microbiol 2007. 9:2055-2069 17419714
29. Bourke E Bosisio D Golay J Polentarutti N Mantovani A The toll-like receptor repertoire of human B lymphocytes: Inducible and selective expression of TLR9 and TLR10 in normal and transformed cells Blood 2003, 102:956-63 12689944
30. Hartmann G Krieg AM Mechanism and function of a newly identified CpG DNA motif in human primary B cells J Immunol 2000, 164:944-53 10623843
31. Martin DR Marlowe RL Ahearn JM Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells J Virol 1994, 68:4716-26 236411 7913508
32. Shannon-Lowe C Baldwin G Feederle R Bell A Rickinson A Delecluse HJ Epstein-Barr virus-induced B-cell transformation: Quantitating events from virus binding to cell outgrowth J Gen Virol 2005, 86:3009-19 16227222
33. Hurley EA Thorley-Lawson DA B cell activation and the establishment of Epstein-Barr virus latency J Exp Med 1988, 168:2059-75 2189139 2848918
34. Wroblewski JM Copple A Batson LP Landers CD Yannelli JR Cell surface phenotyping and cytokine production of Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (LCLs) J Immunol Methods 2002, 264:19-28 12191505
35. Fearon K Marshall JD Abbate C Subramanian S Yee P Gregorio J Teshima G Ott G Tuck S Van Nest G Coffmanet RL A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production Eur J Immunol 2003, 33:2114-22 12884285
36. von Muller L Schliep C Storck M Hampl W Schmid T Abendroth D Mertens T Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplant J Med Virol 2006, 78:394-399 16419118
37. Puius Y Snydman D Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: Current approach and future challenges Curr Opin Infect Dis 2007, 20:419-24 17609603
38. Schrader JW McLean GR Location, location, timing: Analysis of cytomegalovirus epitopes for neutralizing antibodies Immunol Lett 2007, 112:58-60 17714794
39. Revello MG Zavattoni M Furione M Fabbri E Gerna G Preconceptional primary human cytomegalovirus infection and risk of congenital infections J Infect Dis 2006, 193:783-787 16479511
40. Nigro G Adler SP La Torre R Best AM Passive immunization during pregnancy for congenital cytomegalovirus infection N Engl J Med 2005, 353:1350-62 16192480
41. Sokos DR Berger M Lazarus HM Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2002, 8:117-30 11939601
42. Klenovsek K Weisel F Schneider A Appelt U Jonjic S Messerle M Bradel-Tretheway B Winkler TH Mach M Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells Blood 2007, 110:3472-9 17656648
43. Marasco WA Sui J The growth and potential of human antiviral monoclonal antibody therapeutics Nat Biotechnol 2007, 25:1421-34 18066039
44. Mach M Antibody-mediated neutralization of infectivity Cytomegaloviruses: Molecular Biology and Immunology Norfolk, U.K.: Caister Academic Press Reddehase MJ 2006, 265-284 http://www.horizonpress.com
45. Burton DR Saphire EO Parren PW A model for neutralization of viruses based on antibody coating of the virion surface Curr Top Microbiol Immunol 2001, 260:109-43 11443871
46. Parren PW Burton DR The antiviral activity of antibodies in vitro and in vivo Adv Immunol 2001, 77:195-262 11293117
47. Bregenholt S Jensen A Lantto J Hyldig S Haurum JS Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections Curr Pharm Des 2006, 12:2007-15 16787244
48. Andreoni M Faircloth M Vugler L Britt WJ A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus J Virol Methods 1989, 23:157-67 2542350
49. Revello MG Lilleri D Zavattoni M Stronati M Bollani L Middeldorp JM Gerna G Human cytomegalovirus immediate-early messenger RNA in blood of pregnant women with primary infection and of congenitally infected newborns J Infect Dis 2001, 184:1078-81 11574926
50. Caposio P Dreano M Garotta G Gribaudo G Landolfo S Human cytomegalovirus stimulates cellular IKK2 activity and requires the enzyme for productive replication J Virol 2004, 78:3190-3195 353729 14990741
51. Qadri I Navarro D Paz P Pereira L Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus J Gen Virol 1992, 73:2913-21 1279102
52. Kropff B Landini MP Mach M An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus J Med Virol 1993, 39:187-95 8385703
53. Urban M Britt W Mach M The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific J Virol 1992, 66:1303-11 240851 1371164
54. Giudicelli V Chaume D Lefranc MP IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis Nucleic Acids Res 2004, 32:W435-40 441550 15215425